Linked Life Data

20552343

Source:http://linkedlifedata.com/resource/pubmed/id/20552343

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-6-16
pubmed:abstractText
The development of tumor hypoxia during illumination for photodynamic therapy (PDT) can negatively affect treatment outcome. Furthermore, the spatial distribution of this hypoxia may impact the balance between tumor cell damage and vascular damage as mechanisms of photodynamic effect. The hypoxia markers EF3 [(2-(2-nitroimidazol-1 [H]-yl)-N-(3,3,3-trifluoropropyl)acetamide)] or EF5 [(2-(2-nitroimidazol-1 [H]-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide)] can provide a quantitative description of the intratumor distribution of hypoxia during PDT. In vivo perfusion labeling coupled with immunohistochemical staining for vascular structure can provide accompanying information on the status of tumor blood flow at treatment conclusion. Taken together these data can be used to access the relative spatial distributions of hypoxia and perfusion during PDT.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1940-6029
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
635
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
107-20
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Hypoxia and perfusion labeling during photodynamic therapy.
pubmed:affiliation
Department of Radiation Oncology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural